Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposomal Bupivicaine (bupivacaine liposome) (Pacira BioSciences)
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
Bupivacaine liposome is an extended-release formulation of the amide-type local anesthetic bupivacaine, utilizing the DepoFoam multivesicular liposomal delivery technology. This system allows for the controlled release of the drug over an extended period, typically up to 72 hours, following a single administration. The mechanism of action involves the reversible blockade of voltage-gated sodium channels on nerve membranes, which prevents the initiation and conduction of nerve impulses, thereby providing localized analgesia. Developed by Pacira BioSciences, it is FDA-approved for postsurgical local infiltration in adults and children (6 years and older) and for specific regional nerve blocks, such as interscalene brachial plexus block, to manage acute postoperative pain while potentially reducing the need for systemic opioids.
- Brand names
- Exparel
- Other names
- Liposomal BupivacaineBupivacaine Liposome Injectable Suspension
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on Liposomal Bupivicaine (bupivacaine liposome) (Pacira BioSciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liposomal Bupivicaine (bupivacaine liposome) (Pacira BioSciences).